Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, outcomes were similar among patients who had undergone transcatheter aortic-val...

Designing, enrolling in and completing randomized clinical trials in the cardiac intensive care unit (CICU) are fraught with challenges that hinder progress in advancing patient care. Low recruitment ...

This study evaluates the effectiveness and safety of semaglutide and tirzepatide in patients with cardiometabolic heart failure with preserved ejection fraction in clinical practice.

Connecting the Dots Between Ancient Stoicism, Modern Science, and the Path to Healing Others

In this episode of JACC Deep Dive, Dr. Harlan Krumholz explores new insights from a post hoc analysis of the MASTER DAPT trial, highlighting the real-world burden of ischemic and bleeding events in high bleeding risk patients after PCI. By examining recurrent—not just first—events, the study sheds light on how abbreviated dual antiplatelet therapy (DAPT) impacts total clinical outcomes. Key findings include reduced bleeding without increased ischemic risk and a notable clustering of ischemic events following bleeding. This analysis advances the conversation around patient-centered endpoints and the evolving science of recurrent event modeling in cardiology.

Physician. Dad. Traveler. Photographer. Global Rounds is my take on the world — in images, stories, and ideas worth sharing. Click to read Global Rounds with Ali Darwish, a Substack publication. Launc...

In this mini focus issue of JACC This Week, Editor-in-Chief Dr. Harlan Krumholz explores the evolving landscape of cardiac amyloidosis care. From structural and biomarker findings in the HELIOS-B subs...